Laura C Coates Selected Research

Psoriatic Arthritis

11/2022	The need for clarity on the use of glucocorticoids for people with psoriatic arthritis: a call for consensus.
11/2022	Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.
10/2022	Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
10/2022	Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
7/2022	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
7/2022	Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC.
6/2022	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
1/2022	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
1/2022	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
1/2022	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura C Coates Research Topics

Disease

63	Psoriatic Arthritis 11/2022 - 07/2010
20	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 10/2012
13	Pain (Aches) 11/2022 - 04/2009
11	Arthritis (Polyarthritis) 01/2022 - 12/2009
8	Fatigue 11/2022 - 06/2018
6	Ankylosing Spondylitis 01/2021 - 04/2009
5	Chronic Disease (Chronic Diseases) 01/2022 - 06/2018
4	Inflammation (Inflammations) 10/2021 - 07/2008
3	Rheumatoid Arthritis 01/2022 - 09/2016
3	Necrosis 01/2022 - 02/2010
2	Infections 01/2022 - 08/2013
2	COVID-19 01/2022 - 01/2021
2	Axial Spondyloarthritis 01/2022 - 01/2021
2	Skin Diseases (Skin Disease) 01/2019 - 01/2018
2	Edema (Dropsy) 04/2009 - 07/2008
1	Atopic Dermatitis (Atopic Eczema) 01/2022
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022
1	Opportunistic Infections (Opportunistic Infection) 01/2022
1	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 01/2022
1	Skin Manifestations 01/2022
1	Acquired Immunodeficiency Syndrome (AIDS) 11/2021
1	Chronic Pain 01/2020
1	Pneumonia (Pneumonitis) 12/2018
1	Musculoskeletal Diseases (Musculoskeletal Disease) 01/2016
1	Joint Diseases (Joint Disease) 11/2014
1	Neoplasms (Cancer) 08/2013
1	Disease Progression 03/2011
1	Spondylarthropathies 02/2010
1	Back Pain (Backache) 04/2009
1	Spondylarthritis (Spinal Arthritis) 04/2009
1	Sacroiliitis 04/2009

Drug/Important Bio-Agent (IBA)

13	ametantrone (HAQ)IBA 01/2022 - 02/2016
11	Antirheumatic Agents (DMARD)IBA 10/2022 - 12/2015
8	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 02/2016
8	Biological ProductsIBA 01/2022 - 08/2013
7	secukinumabIBA 01/2022 - 10/2018
5	Biomarkers (Surrogate Marker)IBA 06/2018 - 07/2008
4	ixekizumabIBA 10/2022 - 01/2017
4	tofacitinibIBA 01/2022 - 12/2018
3	guselkumabIBA 11/2022 - 01/2022
3	Adalimumab (Humira)FDA Link 01/2022 - 01/2017
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021 - 12/2009
3	Etanercept (Enbrel)FDA Link 01/2021 - 11/2010
3	Janus Kinase InhibitorsIBA 09/2020 - 10/2018
3	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 02/2010
3	golimumab FDA Link 01/2019 - 02/2016
2	Rheumatoid FactorIBA 12/2021 - 10/2012
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 12/2009
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
2	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2021 - 04/2009
2	C-Reactive ProteinIBA 01/2021 - 01/2020
2	Janus Kinase 1IBA 01/2020 - 12/2018
2	GLPG0634IBA 01/2020 - 12/2018
2	apremilastIBA 01/2020 - 01/2020
2	Infliximab (Remicade)FDA Link 07/2010 - 04/2009
1	GlucocorticoidsIBA 11/2022
1	bimekizumabIBA 07/2022
1	upadacitinibIBA 07/2022
1	VaccinesIBA 01/2022
1	cyclic citrullinated peptideIBA 12/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021
1	propylene diquat (PDQ(+))IBA 01/2020
1	amsonic acid (DAS)IBA 01/2020
1	Biosimilar PharmaceuticalsIBA 06/2018
1	Alendronate (Alendronate Sodium)FDA LinkGeneric 05/2017
1	CytokinesIBA 12/2016
1	ElementsIBA 12/2015
1	calinIBA 04/2009

Therapy/Procedure

24	Therapeutics 01/2022 - 04/2009
2	Biological Therapy 01/2021 - 07/2013
2	Injections 01/2021 - 12/2009
1	Precision Medicine 01/2018
1	Immunomodulation 12/2016
1	Drug Therapy (Chemotherapy) 11/2014